Mylan Wins Final Approval for Generic Hypertension Drug
Posted on: Tuesday, 29 July 2008, 09:01 CDT
Mylan has announced that its subsidiary, Mylan Pharmaceuticals, received final approval from the FDA for its abbreviated new drug application for nisoldipine extended-release tablets, 20mg, 30mg and 40mg.
Mylan's nisoldipine extended-release (ER) tablets, indicated for the treatment of hypertension, are the generic version of Sciele Pharma's Sular ER tablets.
Mylan's Nisoldipine ER, which is being shipped immediately, is said to be the first generic version of Sular ER to be introduced in the US. Currently, Mylan has 93 abbreviated new drug applications pending FDA approval, 21 of which are potential first-to-file opportunities.
Source: Datamonitor
Related Articles
- Mylan Announces Final FDA Approval for Doxycycline Tablets
- Mylan Announces Final FDA Approval for Topiramate Tablets
- Mylan Announces Final FDA Approval for Cilostazol Tablets
- Mylan Announces Tentative Approval for Finasteride Tablets USP, 5mg
- Mylan Announces Tentative Approval for Fexofenadine Hydrochloride Tablets
- Mylan Announces Tentative Approval for Carvedilol Tablets
- Mylan Announces Tentative Approval for Rabeprazole Sodium Delayed-Release Tablets
- Mylan Announces Final Approval for Bisoprolol Fumarate Tablets, USP
- Mylan Announces Final FDA Approval for Glimepiride Tablets
- Mylan Receives Approval for Mercaptopurine Tablets USP, 50 Mg
Rating: 3.5 / 5 (6 votes)
 |
 |
Rate this article:
User Comments (0)
RSS Feeds